



NSG BIO

News Release

NETRI WINS 2026 AMGEN X NSG GOLDEN TICKET FOR ITS PROPRIETARY HUMAN NEURONS-AS-A-SENSOR NEUROFLUIDICS PLATFORM

Now in its fifth year, the programme connects biotech startups with expertise, infrastructure and ecosystem support to help advance science that serves patients.

16 July 2026, Singapore – NETRI, a TechBio company combining human neuron-based technology and AI-powered analytics to improve drug development, has been named the winner of the 2026 Amgen x NSG BioLabs Golden Ticket in Singapore. The award is part of a joint programme by Amgen, a leader in biologic medicines, and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices.

Now in its fifth year, the Golden Ticket programme supports high-potential biotechnology startups by providing access to world-class infrastructure, expert mentorship and strategic resources that help accelerate innovation and strengthen pathways from discovery to real-world impact. As this year's recipient, NETRI will receive a one-year residency at NSG BioLabs, including access to certified BSL-2 laboratory facilities, as well as networking opportunities through Amgen's ecosystem of scientific and business leaders.

NETRI was selected following an interactive pitch session reviewed by Amgen and NSG's scientific committee. The company impressed judges with its innovative approach to one of drug development's most enduring challenges: predicting whether potential therapies will be safe and effective before they enter clinical trials. Its proprietary human neuron-based neurofluidics platform combines New Approach Methodologies (NAMs) technology with AI-powered analytics to deliver earlier, more predictive insights, helping researchers make faster, better-informed decisions while reducing reliance on animal testing. Together, these strengths distinguished NETRI as the 2026 Golden Ticket winner.

"NETRI stood out for its innovative approach to addressing a significant challenge in drug development and for the strength of its scientific vision," said **Dr Alan Russell, Vice President, Large Molecule Discovery, and Head, R&D Technology & Innovation at Amgen.** "The company reflects the kind of thinking that can help advance how new medicines are developed and evaluated. At Amgen, we believe great science reaches its full

potential when it can be translated into meaningful patient impact. Through the Golden Ticket programme, we are proud to support innovators whose ideas have the potential to advance science and improve how future therapies are developed."

Hasyim Sim, Chief Operating Officer at NSG BioLabs, added: "Biotech startups need more than laboratory space. They need an environment where they can move quickly, learn from experienced partners and build momentum at critical stages of growth. That is what the Golden Ticket programme is designed to provide. As Singapore's biotech ecosystem continues to evolve, it has been encouraging to see each Golden Ticket cohort advance their science, build partnerships and strengthen their pathways to commercialization. We are excited to support companies like NETRI as they take the next step in translating promising innovation into real-world impact."

Thibault Honegger, CEO and Co-founder, NETRI said: "We are honoured to receive the Amgen x NSG BioLabs Golden Ticket, which marks an important step in the international deployment of NETRI's Neuron-as-a-Sensor technology. Our goal is to use human neurons as functional biological sensors to generate decision-grade insights for preclinical safety and drug discovery, helping pharmaceutical teams better predict safety and efficacy before clinical trials. Singapore offers a highly strategic environment for this next phase, combining world-class biotech infrastructure, access to dynamic cell biology capabilities, strong AI-driven drug discovery ecosystems and proximity to regional partners. Through NSG BioLabs and the opportunity to engage with Amgen's scientific and business teams, we aim to strengthen the robustness, transferability and regulatory readiness of our platform, supporting the broader adoption of New Approach Methodologies in drug development"

NETRI joins a growing list of previous Golden Ticket recipients in Singapore, including [Singzyme](#), [PairX Bio](#), [VerImmune](#) and [Albatroz Therapeutics](#). These companies have leveraged the programme's access, expertise and visibility to further their research, raise funding, and expand partnerships.

Powering Biotech from Discovery to Impact

The award presentation was followed by a panel discussion featuring speakers from Amgen, the Singapore Economic Development Board, Enterprise Singapore, and EDBI (arm of SG Growth Capital, investment platform of EDB and Enterprise Singapore) who shared perspectives on what it takes to move promising biotech innovations from the laboratory to real-world patient impact. The discussion underscored that while scientific excellence is a critical foundation, the ability to make informed decisions, establish strategic partnerships early, and access the right ecosystem support are equally important in advancing innovation. Panellists also highlighted the value of a collaborative ecosystem that brings together research capabilities, talent, capital, industry networks and emerging technologies, such as artificial intelligence, to help biotech companies accelerate development and grow from Singapore onto the global stage.

"Singapore's biotech ecosystem is entering a new phase of maturity, with a growing pipeline of companies translating world-class science into globally relevant innovation,"

said **Jolene Ooi, Partner, EDBI**. "Realising the full potential of breakthrough science requires long-term commitment, strategic partnerships and access to the right expertise at every stage of growth. We remain committed to working across the biotech ecosystem to help the next generation of globally competitive biotech companies scale from Singapore to global markets."

For more information on the Golden Ticket programme, visit [NSG Bio Tomorrow](#).

###

About Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.

Amgen has been [consistently recognized](#) for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit [Amgen.com](#) and follow Amgen on [X](#), [LinkedIn](#), [Instagram](#), [YouTube](#), [Facebook](#), [TikTok](#) and [Threads](#).

About NSG BioLabs

Founded with a focus on supporting biotech innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 70,000 sq ft within Singapore's biomedical science clusters, Biopolis and Singapore Science Park.

By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG BioLabs ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients. For more information, visit [www.nsgbio.com](#)

About NETRI

NETRI is a TechBio industrial start-up whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology-related adverse events, dermo-cosmetics, neurological disorders and neurotoxicity.

Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format, enabling innervation and vascularization of any organ - NeuroFluidics™ MEA - which acts as a data generation hub for its digital signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, Organ-on-chip hardware, AI-trained software, digital libraries and methods.

For more information, visit www.netri.com

Media contact

Mindy Chee, Amgen mchee01@amgen.com

Petrina Loh, Sandpiper petrina.loh@sandpipercomms.com

###